ArticleTropical animal health and production2026
Antibody kinetics and shedding dynamics of MERS-CoV in dromedary camels from different production systems in Kenya: a longitudinal cohort study.
Article in Tropical animal health and production, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drivers of Viral Spillover: An Examination of How Pathogens Spread.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding long-term antibody kinetics in different camel production systems is crucial for risk assessment for Middle East respiratory syndrome coronavirus (MERS-CoV), a zoonotic pathogen first detected in humans in Saudi Arabia. Though the virus is endemic in dromedary camels across Africa, the Middle East, and parts of South Asia, zoonotic transmission outside of the Arabian Peninsula is undocumented. A retrospective analysis of longitudinal surveillance data of MERS-CoV was conducted on 2460 serum samples collected from 174 camels in three high-risk counties of Kenya from April 2018 to March 2021. Data were analyzed using descriptive statistics, logistic regression, and survival analysis. A total of 93/174 (53.4%) camels were seropositive at least once (animal-level), while 882/2460 (35.85%) of all serum samples tested seropositive (sample-level). Data were analyzed using descriptive statistics, logistic regression and survival analysis. A total of 93/174 (53.4%) camels were seropositive at least once. All camels in the pastoral system seroconverted, exhibiting significantly higher odds of seropositivity (OR: 9.4) compared to ranched camels, and camels above 3 years (OR: 21.2) are more likely to be seropositive compared to young ones. The median duration of seropositivity was 21 days (IQR: 11–53), varying significantly by geographical site. Camels from Garissa and Soysambu have 97% (aOR: 0.03 (CI95%: 0.001–0.79; p = 0.035) and 98% (aOR: 0.02 (CI95%: 0.001–0.48; p = 0.015) longer durations of seropositivity than those from Isiolo. The study demonstrates the spatiotemporal and biological variability of antibody levels, indicative of fluctuations in viral exposure and the resultant immune response among the camel herds. Thus, camel production practices, not just seroprevalence, drive MERS-CoV infection dynamics, demanding surveillance and stewardship strategies that are tailored to specific production systems to effectively mitigate zoonotic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.